文献速递淋巴瘤

RELEVANCE研究六年结果:来那度胺联合利妥昔单抗(R2)对比利妥昔单抗联合化疗后利妥昔单抗维持治疗初治晚期滤泡性淋巴瘤

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
PubMed 文献 · J Clin Oncol · 2022-08-10

RELEVANCE试验将初治1-3a级晚期滤泡性淋巴瘤患者1:1随机分配至R2方案或R-chemo方案,后续均接受利妥昔单抗维持治疗。中位随访72个月时,R2组与R-chemo组6年无进展生存率分别为60%和59%(HR=1.03,95%CI 0.84-1.27),6年总生存率两组均为89%,R2持续显示与R-chemo相当的持久疗效和安全性,并提供可接受的无化疗替代方案。

要点

  • 中位随访72个月,R2组与R-chemo组6年无进展生存率分别为60%和59%(HR=1.03,95%CI 0.84-1.27)。
  • 两组6年总生存率均估计为89%,中位无进展生存和总生存均未达到。
  • R2组与R-chemo组年转化率分别为0.68%和0.45%,第二原发恶性肿瘤发生率分别为11%和13%(P=0.34),未观察新的安全性信号。

核心结论

  • 在初治晚期滤泡性淋巴瘤患者中,R2持续显示与R-chemo相当的持久疗效和安全性,并提供可接受的无化疗替代方案。

研究设计与样本

  • RELEVANCE试验(ClinicalTrials.gov标识符NCT01650701)将既往未治疗的1-3a级滤泡性淋巴瘤患者按1:1随机分配至R2组或R-chemo组,后续接受利妥昔单抗维持治疗。
  • 共同主要终点为第120周完全缓解(确认/未确认)和无进展生存。
  • 本次报告为RELEVANCE试验中位随访72个月的第二次中期分析。

主要发现

  • 中位随访72个月时,R2组与R-chemo组6年无进展生存率分别为60%和59%(HR=1.03,95%CI 0.84-1.27)。
  • 两组6年总生存率均估计为89%,两组中位无进展生存和总生存均未达到。
  • 疾病进展后总缓解率R2组为61%、R-chemo组为59%,进展后5年估计生存率R2组为69%、R-chemo组为74%。
  • R2组与R-chemo组年转化率分别为0.68%和0.45%,第二原发恶性肿瘤发生率分别为11%和13%(P=0.34)。
  • 未观察到新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R2) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL). We report the second interim analysis of the RELEVANCE trial after 6 years of follow-up. Patients with previously untreated grade 1-3a FL were assigned 1:1 to R2 or R-chemo, followed by rituximab maintenance. Coprimary end points were complete response (confirmed/unconfirmed) at week 120 and progression-free survival (PFS). At median follow-up of 72 months, 6-year PFS was 60% and 59% for R2 and R-chemo, respectively (hazard ratio = 1.03 [95% CI, 0.84 to 1.27]). Six-year overall survival was estimated to be 89% in both groups. Median PFS and overall survival were not reached in either group. Overall response after progression was 61% and 59%, and 5-year estimated survival rate after progression was 69% and 74% in the R2 and R-chemo groups, respectively. The transformation rate per year in the R2 and R-chemo groups was 0.68% and 0.45%, and secondary primary malignancies occurred in 11% and 13% (P = .34), respectively. No new safety signals were observed. R2 continues to demonstrate comparable, durable efficacy and safety versus R-chemo in previously untreated patients with FL and provides an acceptable chemo-free alternative.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morschhauser F, Nastoupil L, Feugier P, et al. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022. PMID: 35947804. doi:10.1200/JCO.22.00843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。